| 翻訳と辞書 |
Naproxcinod
Naproxcinod (nitronaproxen) is a non-steroidal anti-inflammatory drug (NSAID) developed by the French pharmaceutical company NicOx. It is a derivative of naproxen with a nitroxybutyl ester to allow it to also act as a nitric oxide (NO) donor. This second mechanism of action makes naproxcinod the first in a new class of drugs, the cyclooxygenase inhibiting nitric oxide donators (CINODs), that are hoped to produce similar analgesic efficacy to traditional NSAIDs, but with less gastrointestinal and cardiovascular side effects.
On December 2006, ''Scientific American'' distinguished naproxcinod as one of the ten most promising treatments for the world's biggest health threats;〔(''Special Report: 10 Promising Treatments for World's Biggest Health Threats'', By Charles Q. Choi. 2006 )〕 however, in 2010 the U.S. Food and Drug Administration determined that further clinical trials would be needed to obtain approval.〔
==Current situation in pain treatment==
Many people are currently relying on traditional non-steroidal anti-inflammatory drugs and COX-2 inhibitors (for example celecoxib) to treat chronic pain and inflammation. COX-2 inhibitors have been associated with an increased risk of serious cardiovascular events such as strokes or heart attacks. Therefore, there is an unmet need for safer medications. This need is particularly acute among patients with high cardiovascular risk like hypertension which represents 50% of osteoarthritis sufferers.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Naproxcinod」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|